BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • September 2024
  • August 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

Cancer Treatment

3 posts
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

  • BioTech Health X
  • July 20, 2022
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
0 Shares
0
0
0
0
0
0
0
2seventy-bio-Secure-170-Million-Extending-Cash-Runway-Into-2025

Biotech News2seventy bio Secure $170 Million Extending Cash Runway Into 2025

  • BioTech Health X
  • March 16, 2022
2seventy bio (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that it has agreed to sell…
0 Shares
0
0
0
0
0
0
0
Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head Neck Patients in Phase 3 Trial

Biotech NewsCel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial

  • BioTech Health X
  • June 28, 2021
Data Shows Significant Overall Survival Benefit for Cancer Patients with Multikine Treatment Regimen Followed by Surgery & Radiotherapy…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • CEL-SCI’s Multikine Immunotherapy Boosts 5-Year Survival Rate in Head and Neck Cancer
  • Novartis Pioneers RNA Therapeutics with Borealis Biosciences for Kidney Diseases
  • Genentech’s Strategic Pivot: The Closure of Its Cancer Immunology Unit
  • Breakthrough in Alzheimer’s Treatment: Biogen and Eisai’s Leqembi Wins UK Approval
  • Vera Therapeutics’ Atacicept Shows Promising Results in Phase 2b ORIGIN Trial for IgA Nephropathy
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • September 16, 2024
    CEL-SCI’s Multikine Immunotherapy Boosts 5-Year Survival Rate in Head and Neck Cancer
    CEL-SCI Multikine Immunotherapy Boosts 5-Year Survival Rate in Head and Neck Cancer
    • August 22, 2024
    Novartis Pioneers RNA Therapeutics with Borealis Biosciences for Kidney Diseases
    Novartis Pioneers RNA Therapeutics with Borealis Biosciences for Kidney Diseases
    • August 22, 2024
    Genentech’s Strategic Pivot: The Closure of Its Cancer Immunology Unit
    Genentech Strategic Pivot The Closure of Its Cancer Immunology Unit
    • August 22, 2024
    Breakthrough in Alzheimer’s Treatment: Biogen and Eisai’s Leqembi Wins UK Approval
    Breakthrough in Alzheimers Treatment Biogen and Eisais Leqembi Wins UK Approval
    • May 25, 2024
    Vera Therapeutics’ Atacicept Shows Promising Results in Phase 2b ORIGIN Trial for IgA Nephropathy
    Vera Therapeutics Atacicept Shows Promising Results in Phase 2b ORIGIN Trial for IgA Nephropathy
Recent Posts
  • Ozempic Shows Lower Risk of Kidney and Heart Complications in Diabetic Patients
    Ozempic Shows Lower Risk of Kidney and Heart Complications in Diabetic Patients
    • May 24, 2024
  • Eli Lilly Announces Historic 5.3 Billion Investment to Expand Indiana Manufacturing for Diabetes and Weight Loss Drugs
    Eli Lilly Announces Historic $5.3 Billion Investment to Expand Indiana Manufacturing for Diabetes and Weight Loss Drugs
    • May 24, 2024
  • Guardant Health Shield Blood Test for Colorectal Cancer Receives FDA Advisory Panel Endorsement
    Guardant Health’s Shield Blood Test for Colorectal Cancer Receives FDA Advisory Panel Endorsement
    • May 24, 2024
Categories
  • BioTech CEO Interviews (5)
  • Biotech Info (1)
  • Biotech News (68)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top